Vicriviroc (SCH 417690) Treatment Protocol in HIV-Infected Subjects: A Rollover Study for ACTG Protocol A5211
Latest Information Update: 09 May 2022
Price :
$35 *
At a glance
- Drugs Vicriviroc (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 18 Nov 2010 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.
- 18 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Jun 2010 Planned end date changed from 1 Dec 2010 to 1 Dec 2011 as reported by ClinicalTrials.gov.